Creative Biolabs, a global leader in antibody engineering, today announced its optimization of ADCC and Fc-mediated effector functions. SHIRLEY, NY, UNITED STATES ...

- WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy by producing afucosylated antibodies with the ability to increase antibody-dependent cell-mediated ...

B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...

Therapeutic antibodies are now the major class of successful protein drugs with many more in development to target a variety of major diseases. An important and desirable biological activity of most ...

Immune checkpoint inhibitors (ICIs), a powerful form of immunotherapy, have revolutionized cancer treatment by unleashing the body's own immune system to fight tumors. These compounds target the ...

Researchers from Nordic Nanovector ASA presented the discovery of a novel humanized anti-CD37 monoclonal antibody, NNV-024, engineered to exhibit a strong antibody-dependent cellular cytotoxicity ...

An absence of fucose residues on the antibody immunoglobulin γ (IgG) constant (Fc) region N-glycan moiety has been shown to increase the binding affinity to IgG-Fc-receptor (FcγR) IIIa. Since this ...

ADCs integrate monoclonal antibodies with cytotoxic payloads, offering new treatment options for NSCLC, including biomarker-selected and biomarker-agnostic patients. ADCs are composed of an antibody, ...